Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine or Decitabine With Sonidegib in Myeloid Malignancies
NCT02129101Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- May 2014
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in Myeloid malignancy, acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and 3 more, sponsored by Mayo Clinic. Primary endpoints: Best overall response (CR or CRi) and Maximum Tolerated Dose at 42 days. Started May 2014; status: completed.
02
Drugs
sonidegib
03
Conditions
Myeloid malignancyacute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT02129101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129101.